AstraZeneca: Datopotamab Deruxtecan Improved Progression-Free Survival vs. Chemotherapy in Patients With Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial
October 24, 2023
October 24, 2023
WILMINGTON, Delaware, Oct. 24 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan reduced the risk of disease progression or death by 25% in overall population and by 37% in patients with non-squamous tumors
Datopotamab deruxtecan is the first antibody drug conjugate to demonstrate statistically significant improvement in PFS over docetaxel in this setting of . . .
* * *
AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan reduced the risk of disease progression or death by 25% in overall population and by 37% in patients with non-squamous tumors
Datopotamab deruxtecan is the first antibody drug conjugate to demonstrate statistically significant improvement in PFS over docetaxel in this setting of . . .